Table 1 Patient characteristics
From: Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT
Groups | Total (n = 37) | Group A: ATTR cardiac amyloidosis (n = 6) | Group B: AL cardiac amyloidosis (n = 10) | Group C: others (n = 21) | p value |
|---|---|---|---|---|---|
Demographics | |||||
 Age (years) | 57.7 ± 13.2 | 58 ± 6 | 61 ± 3 | 56 ± 2 | 0.579 |
 Male sex (%) | 70.3 | 66.7 | 90.0 | 61.9 | 0.327 |
 BMI (kg/m2) | 23.7 ± 3.6 | 22.4 ± 1.7 | 22.7 ± 0.9 | 24.5 ± 0.8 | 0.256 |
Biopsy | |||||
 EMB (%) | 16.2 | 16.7 | 40.0 | 4.8 | 0.028 |
 Other tissue (%) | 27.0 | 33.3 | 50.0 | 14.3 | 0.049 |
Laboratory | |||||
 Abnormal serum/urine IFE (%) | 10.8 | 0.0 | 40.0 | 0.0 | 0.006 |
 Abnormal sFLC (%) | 24.3 | 0.0 | 90.0 | 0.0 | < 0.0001 |
Echocardiography | |||||
 Abnormal (%) | 10.8 | 83.3 | 80.0 | 19.0 | < 0.0001 |
 LVEF < 50% (%) | 5.4 | 0.0 | 20 | 0.0 | 0.090 |
 IVS or LVPW > 12 mm (%) | 54.1 | 83.3 | 100.0 | 23.8 | < 0.0001 |
Others | |||||
 Heart rate (beats per min) | 82.2 ± 13.6 | 81.8 ± 3.0 | 83.9 ± 4.0 | 81.57 ± 3.4 | 0.908 |
 Hypertension (%) | 16.2 | 0.0 | 30.0 | 14.4 | 0.402 |